Defined Terms Section. Alliance Manager 3.1 Auditor 10.4(c) Bankruptcy Event 13.5 Bankrupt Party 15.13 Claims 11.1 Clinical Supply Agreement 7.1 Commercialization Plan 6.2(a) Commercial Supply Agreement 7.2(a) Competing Program 15.5(b) Confidentiality Agreement 1.20 DMF 5.1(b) Effective Date Preamble Enforcing Party 9.4(c) Executive Officer 14.1 First Supplemental Development Plan 4.2 GAAP 1.1 Global Development Plan 4.3(d) Global Strategy 4.3(d) Global Territory Expansion Opportunity 6.6 GQP Agreement 5.1(b) ICC 14.2 Indemnified Party 11.3 Indemnifying Party 11.3 Infringement 9.4(a) Infringement Action 9.5 Initial Development Plan 4.2 Initial Purchase Price Payment 8.5(a)(i) JGAAP 1.1 Joint Inventions 9.1(c)(iii) Joint Steering Committee 3.2(a) Kaken Preamble Kaken Housemarks 9.6(b) Kaken Indemnitees 11.1 Kaken Inventions 9.1(c)(ii) Kaken Product Mark 9.6(a) Kaken Sublicense Agreement 2.1(c) Lilly 1.86 Losses 11.1 Defined Terms Section Major Spruce Partner 2.2 Manufacturing Technology Transfer Agreement 7.2(b) NDA 1.56 Non-Bankrupt Party 15.13 Party Preamble Payment 8.9(b) Pharmacovigilance Agreement 5.8 Product Materials 4.6 Reconciliation Amount 8.5(a)(i) Remedial Action 5.9 Right of Reference 5.5 ROFN 6.6 ROFN Exercise Period 6.6 ROFN Exercise Notice 6.6 ROFN Negotiation Period 6.6 ROFN Offer Notice 6.6 Royalty Term 8.4(b) SEC 12.3(c) Spruce Preamble Spruce Indemnitees 11.2 Spruce Inventions 9.1(c)(i) Spruce Partner 2.2 Step-In Rights 9.2(e) Tax Changing Decision 8.9(b) Tax Documents 8.1 Term 13.1 Territory Development Plan 4.2 Territory Expansion Opportunity 6.6 Transfer Price 8.4(a)(i) Working Group 3.5
Defined Terms Section. Action 2.2(e) Affiliate 6.10(a) Agreement Preamble Bank 2.2(b) Burdensome Condition 1.2(c)(1)(iv) Closing 1.2(a) Closing Date 1.2(a) Company Preamble Company SEC Reports 2.2(g) Company Subsidiary(ies) 2.2(b) Company’s Knowledge 6.10(e) Contemplated Transactions 2.2(c)(1) Disclosure Letter 2.1(a) DTC 4.2(b) Exchange Act 2.2(d) FDIC 2.2(b) Federal Reserve 1.2(c)(1)(iv) FINRA 2.2(o)
Defined Terms Section. Genfit Inventions 9.1(c)(i) Genfit Partner 2.2 ICC 14.2 IFRS 1.1 Indemnified Party 11.3 Indemnifying Party 11.3 Infringement 9.4(a) Infringement Action 9.5 Initial Development Plan 4.2 Joint Inventions 9.1(c)(iii) Joint Steering Committee 3.2(a) Losses 11.1 NDA 1.53 Party Preamble Pharmacovigilance Agreement 5.8 Product Materials 4.6 Remedial Action 5.9 ROFN 2.5(b) ROFN Exercise Period 2.5(b) ROFN Exercise Notice 2.5(b) ROFN Negotiation Period 2.5(b) ROFN Offer Notice 2.5(b) Royalty Term 8.4(b) SEC 12.3(c) Step-In Rights 9.2(d) Tax Withholding 8.9(b) Term 13.1 Terns Preamble Terns Housemarks 9.6(b) Terns Indemnitees 11.1 Terns Inventions 9.1(c)(ii) Terns Product Xxxx 9.6(a) Terns Sublicense Agreement 2.1(c) Third Party Drug Product Supply Agreement 7.2(a)(i) Third Party API Supply Agreement 7.2(b)(i) VAT 8.9(d) Working Group 3.5(a) Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed.
Defined Terms Section. Alliance Manager 2.7 Breaching Party 12.2(a) CDA 9.1 Clinical Operations Sub-Team 2.5(b) Co-Chair 2.3 CRF 2.1(d) CRO 2.6 CRO Agreement 2.1(e) Cure Period 12.2(a) Dispute 13.3(a) ICF 2.1(d) Indemnify 11.1 Infringement 6.3(a) Initial Studies 2.1(a) IRB 2.6 JDC or Joint Development Committee 2.3 JDC Dispute 2.8 Joint Inventions 6.1(e) Joint Patents 6.1(c)(ii) Losses 11.1 Monotherapy Arm 8.11 Monotherapy Study Data 8.11(a) Non-Breaching Party 12.2(a) Non-Prosecuting Party 6.1(c)(ii) Officials 10.9
Defined Terms Section. Prior CRO Agreement 2.1(e) Prior Study Agreement 2.1(d) Proposing Party Exhibit E(b) Prosecuting Party 6.1(c)(ii) Protocol 2.1(b) Publication Dispute 9.5(c) Results 9.5(c) Study Costs 7.1(c) Site Agreement 2.1(d) Study Data 8.1 Study Documentation 2.8(b) Subsequent Study Exhibit E(b) Sunshine Laws 9.6 Supply and Quality Documentation 4.3 Term 12.1 Third Party Claim 11.1 Triple Study 2.1(a) Ventana 8.5(c)(ii) ARTICLE 2
Defined Terms Section. Company Patents 9.2(b) Enforcing Party 9.3(c) Infringement Actions 9.4 Company Housemarks 9.6(b) Company Indemnitees 11.1 Losses 11.1 Claims 11.1 KemPharm Indemnitees 11.2 Indemnified Party 11.3 Indemnifying Party 11.3 Term 13.1 Bankruptcy Event 13.5(a) Bankrupt Party 13.5(b) Code 13.5(b) Non-Bankrupt Party 13.5(b) Payment Assignment 15.5(c) Payment Assignment Notice 15.5.(c) Exclusive Period 15.5(c) Payment ROFR 15.5(c)
Defined Terms Section. Company Employee Benefit Plans 4.10(a) Company ESPP 3.3(e) Company Financial Advisor 1.2(a) Company Incentive Plan 3.3(a) Company Options 3.3(c) Company Permits 4.13 Company Reports 4.6(a) Company Representatives 6.1(a) Company Shares Recitals Company Stockholder Approval 4.22 Company Stock Plans 3.3(e) Company Superior Proposal 6.1(b) Company Takeover Proposal 6.1(a) Confidentiality Agreement 6.1(a) Continuing Employees 6.11(a) Control Date 1.3 Conversion Ratio 3.3(b) Delaware Courts 9.5 Department of Justice 6.13 DGCL Recitals Dissenting Common Stock 3.6 Dow Jxxxx News Release 4.6(a) Effective Time 2.3 Environmental Claim 4.14(d) Environmental Consultant 6.15(a) Environmental Laws 4.14(d) Environmental Permits 4.14(a) ERISA 4.10(a) Exchange Act 1.1(a) Exchange Agent 3.4(a) Foreign Plans 4.10(d) GAAP 4.6(b) Governmental Entity 4.3 Group 8.1(d)(iv) Hazardous Substances 4.14(d) HSR Act 4.5(b) Indemnified Party 6.9(b) Indemnified Parties 6.9(b) Independent Directors 1.3 Intellectual Property 4.16(c) IRS 4.10(c) Laws 4.3 Liens 4.4(g) Litigation 4.7 Material Contracts 4.19 52 Defined Terms Section Merger Recitals Minimum Condition Annex I Nasdaq 3.3(b)
Defined Terms Section. 3D Medicines Preamble 3D Medicines Housemarks 9.6(b) 3D Medicines Indemnitees 11.1 3D Medicines Inventions 9.1(c)(ii) 3D Medicines Product Xxxx 9.6(a) 3D Medicines Sublicense Agreement 2.1(c) Accused Party 9.5 Agreement Preamble Alliance Manager 3.1 Aravive Preamble Aravive Indemnitees 11.2 Aravive Inventions 9.1(c)(i) Aravive Licensed Product Opportunity 6.6 Aravive Partner 2.2 Auditor 10.4(c) BLA 1.55 Claims 11.1 Clinical Supply Agreement 7.1(a) Commercialization Plan 6.2(a) Competing Program 15.6(b) Confidentiality Agreement 1.24 Development Plan 4.2 Development Proposal 2.1(a) Effective Date Preamble Enforcing Party 9.4(c) Executive Officer 14.1 First Supplemental Development Plan 4.2 GAAP 1.1 ICC 14.2 IFRS 1.1 Indemnified Party 11.3 Indemnifying Party 11.3 Infringement 9.4(a) Infringement Action 9.5 Initial Development Plan 4.2 Joint Inventions 9.1(c)(iii) Joint Steering Committee 3.2(a) Losses 11.1
Defined Terms Section. Manufacturing Technology Transfer Agreement 7.1(b) NDA 1.55 New Studies 2.1(a) Party Preamble Pharmacovigilance Agreement 5.8 Product Materials 4.6 Remedial Action 5.9 ROFN 6.6 ROFN Exercise Period 6.6 ROFN Exercise Notice 6.6 ROFN Negotiation Period 6.6 ROFN Offer Notice 6.6 XXX 2.5(b) XXX Exercise Period 2.5(b) XXX Exercise Notice 2.5(b) XXX Negotiation Period 2.5(b) XXX Offer Notice 2.5(b) Royalty Term 8.6(b) SEC 12.3(c) Stanford 1.76 Step-In Rights 9.2(d) Term 13.1 VAT 8.11(c) Working Group 3.5
Defined Terms Section. 409A Authorities Section 3.11(e) Adjusted Shareholders’ Equity Section 10.01(f) Agreement Preamble AJCA Section 3.11(e) ALL Section 3.28 Articles of Merger Section 1.02 Bank Section 3.01 Certificate Section 1.06(a) Change in Board Recommendation Section 6.03(b) Claim Section 7.02(a) Closing Section 2.01 Closing Balance Sheet Date Section 6.06 Closing Date Section 2.01 Closing Financial Statements Section 6.06
